The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.
The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.
The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.
There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.
GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.
• Our writers’ share tips for 2026, plus last year’s winners and losers
Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.
M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.
Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.
“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important. These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”
Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.
The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.
While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.
The euro initially tried to rally against the British pound during the trading session on Thursday, but it looks as if the unwinding of negative bets against the British pound continues on Thursday. We initially tried to break above that 50-day EMA, but have given that back, and now it looks like the budget in the United Kingdom has allayed some of the fears that traders had about the British pound, and it is showing up here and many other currency pairs. With that being said, I am looking at a potential breakdown toward the 0.87 level. If we break down below the 0.87 level, I suspect that at that point in time, we make a move down to 0.86 and lower. This does look a lot like a topping pattern, and the sizable candlestick on Wednesday, of course, definitely makes this appear a very probable breakdown.
This market typically is very choppy, to say the least, and as a result, you have to be very cautious, but I also look at this market as one that has been close to a major resistance barrier in the form of 0.89. And as long as we don’t break above there, I don’t know that the behavior of this pair will have changed drastically from a longer-term standpoint. While I don’t necessarily expect a massive shorting opportunity, I do think that overall, we are starting to see a shift in the pattern, and this suggests to me that maybe we have a trend change. It’s still early days, but with a little bit of caution, it is a trade that I might be willing to take.
Ready to trade our daily forecast and analysis? Here’s a list of some of the top forex brokers UK to check out.
Christopher Lewis has been trading Forex and has over 20 years experience in financial markets. Chris has been a regular contributor to Daily Forex since the early days of the site. He writes about Forex for several online publications, including FX Empire, Investing.com, and his own site, aptly named The Trader Guy. Chris favours technical analysis methods to identify his trades and likes to trade equity indices and commodities as well as Forex. He favours a longer-term trading style, and his trades often last for days or weeks.
Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.
The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.
The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.
There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.
GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.
• Our writers’ share tips for 2026, plus last year’s winners and losers
Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.
M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.
Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.
“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important. These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”
Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.
The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.
While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.
XRP price has remained under pressure over the past several weeks, with multiple recovery attempts failing to gain traction. As 2025 comes to an end, the altcoin continues to succumb to bearish momentum after recording a mildly negative year overall.
Weak spot demand and cautious retail participation have weighed on price action. However, institutional interest has emerged as XRP’s primary stabilizing force, preventing deeper drawdowns despite persistent selling.
Institutional investors have been XRP’s most consistent supporters throughout 2025. According to CoinShares data, XRP recorded $70 million in inflows during the week ending December 27. This pushed month-to-date inflows to $424 million, highlighting steady capital allocation even during periods of declining prices.
Sponsored
Sponsored
Notably, XRP outperformed larger digital assets during the same period. Bitcoin recorded $25 million in outflows, while Ethereum saw significantly higher outflows totaling $241 million.
Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.
On a yearly basis, XRP attracted $3.3 billion in inflows, highlighting sustained institutional confidence despite ongoing volatility and legal uncertainties surrounding the broader crypto market.
Institutional support has extended beyond traditional exchange-traded products following the launch of XRP ETFs earlier this year. Since their debut, XRP ETFs have not recorded a single day of net outflows. Only one trading session closed flat, without inflows, reflecting unusually strong consistency in demand.
Sponsored
Sponsored
Speaking exclusively to BeInCrypto, Ray Youssef, CEO of crypto app NoOnes, emphasized that institutional investors are executing structured, long-term strategies.
“XRP’s early December accumulation was a strategic positioning by market participants to catch the ETF momentum upside. As with early Bitcoin and Ethereum ETF launch cycles, institutional investors often accumulate assets before their prices begin to reflect these developments,” Youssef noted.
He further stated that XRP is now observed as a high beta asset with a strong value proposition.
“[This] is thanks to the increased participation of institutional players in the asset’s trading, which is further mainstreaming the asset. Despite the prevailing price weakness, traders still consider the current price points as suitable entry opportunities to capture growth potential once XRP’s performance finally reflects the ETF’s momentum,” stated Youssef.
Long-term holders remain a critical cohort heading into 2026. Historically, this group has played a stabilizing role during market downturns. Over the past year, long-term holders alternated between accumulation and distribution, reflecting uncertainty around XRP’s medium-term prospects.
Sponsored
Sponsored
By Q4 2025, selling activity dominated long-term holder behavior. This shift suggests declining confidence among investors who typically hold through volatility. If this lack of conviction persists into 2026, XRP could face heightened downside risk. Sustained distribution from long-term holders often precedes extended consolidation or deeper corrections.
XRP price traded near $1.87 at the time of writing after suffering a 38% decline during Q4 2025. Year-to-date performance shows the altcoin down 9.7% from its opening price. December failed to generate positive momentum, reinforcing bearish sentiment as the year closed.
Despite this, 2026 may chart an independent course. Ray Youssef noted that January, and potentially the entire first quarter, could remain largely stagnant for XRP.
“XRP will likely continue to consolidate and trade between $2 and $2.50 in January and Q1 2026, unless a decisive macro catalyst emerges. The market has yet to recover from persistent volatility and geopolitical disruptions caused by the strained trade relations. The numerous deleveraging and risk-off episodes have made traders hesitant to increase directional exposure until the market headwinds have entirely dissipated,” Youssef highlighted.
The broader objective remains recovery of recent losses. A sustained move above $3.00 would be required to reestablish bullish structure and open a path toward the $3.66 all-time high.
Sponsored
Sponsored
Downside scenarios remain relevant if selling pressure intensifies. Continued consolidation combined with reduced demand could push XRP lower. A decisive break below the $1.79 support level would likely expose the $1.50 zone. Such a move would invalidate the bullish-neutral thesis and reinforce bearish dominance.
Seasonality adds another layer of caution.
“XRP underperformed in December due to the broader market’s structural weakness. Liquidity contraction, weak risk appetite, and the AI bubble scare sell-off, which spilled into high-risk assets and the entire digital asset market, curtailed the effects of the expected seasonal tailwinds. The crypto market saw one of its worst Q4 performances in almost 7 years,” Youssef further noted.
Historical XRP performance over the past 12 years shows that January delivers an average gain of 3%. However, the median return reflects a 7.8% decline, indicating frequent underperformance.
Thus, unless market sentiment and investor behavior shift significantly, XRP price prediction suggests that the price may struggle during the early months of 2026 before clearer directional trends emerge.
Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.
Here’s a hot tip for tea: Temperature matters. If you’re like many westerners, you may just bring water to a boil and pour it over bagged or loose-leaf tea, regardless of the variety. But it turns out that while boiling water may be the best temperature for brewing black tea, other types of tea require cooler water for the perfect pour.
During a discussion about tips for brewing the perfect tea, Jeannie Liu, founder and owner of Seattle tea shop Miro Tea, explained why overheating the water can be detrimental to your cup of tea. “Tea gets bitter because of over-extraction of its tannins, catechins, and caffeine,” she shared.
Tea leaves contain all sorts of chemicals and nutrients that react differently to a range of temperatures. A general rule is lower temperatures for more delicate teas like green or white, and a higher temperature for more robust infusions, such as black tea. Herbal teas like chamomile or rooibos also like it hot.
While exact tea-steeping temperatures vary slightly depending on which expert you consult, the ranges are similar. The young leaves and buds of white tea need 160 to 185 degrees Fahrenheit, while a good cup of green tea should be steeped at a similar 160 to 180 degrees Fahrenheit. Going up the heat scale, try 185 to 205 degrees Fahrenheit for oolong tea. You can go right up to 212 degrees Fahrenheit for black tea as well as herbal teas. Also, keep in mind that boiling water multiple times depletes it of oxygen, which can lead to less aroma and more astringency in any tea.
With such varying and precise temperatures for tea brewing, it can be helpful to have a temperature-controlled tea kettle. But if you don’t have one, you can use a regular kitchen thermometer, or simply let boiling water cool for a bit before pouring it. You can also watch for the small bubbles that start to form around 160 degrees Fahrenheit, the “crab eyes” that are characteristic around 175 degrees Fahrenheit, and, of course, the common rolling boil that signifies a full 212 degrees Fahrenheit.
As of today, Bitcoin USD (BTCUSD) is trading at $87,877.29, experiencing a slight increase of 0.81%. The big question on traders’ minds now is whether Bitcoin can hit the $92,000 mark in the coming months. Let’s break down the current data, trends, and technical indicators to understand the possibilities.
Bitcoin’s current price stands at $87,877.29, with a daily range between $87,349.52 and $88,000. This aligns with a modest rise of 0.81%, or $705.61, over the last 24 hours. Bitcoin is significantly below its 50-day moving average of $91,712.54 and even further from its 200-day average of $107,608.47, indicating potential bearish sentiment in the short term. The market cap is a robust $1.73 trillion, supported by a relatively high volume of $15.16 billion compared to an average of $508 million.
Technical indicators show mixed signals for Bitcoin. The RSI is at 42.91, approaching the oversold territory, suggesting that a rebound might be possible. The MACD, with a value of -2355.42, reveals bearish momentum, but a positive histogram could indicate a potential crossover in the future. The ADX at 34.98 confirms a strong trend, although not specifying direction. The Bollinger Bands suggest that Bitcoin is near its middle band of $89,354.05, hinting at possible sideways movement. Forecasts can change due to macroeconomic shifts, regulations, or unexpected events affecting the crypto market.
Looking ahead, Meyka AI provides several forecasts: the monthly target is $91,771.03, while the quarterly projection is a bullish $137,052.42. However, the yearly prediction dips to $83,932.49, indicating uncertainty in long-term market conditions. Meanwhile, five-year estimates hover around $133,253.33, suggesting potential growth.
Recent news reports continue to highlight Bitcoin’s popularity among traders but emphasize uncertainty due to volatile market conditions. No significant new events have directly impacted Bitcoin in the last 24 hours, beyond slight market fluctuations. The trend, as indicated by volume spikes and technical indicators, underscores the market’s cautious optimism.
Bitcoin’s path to $92,000 is filled with both challenges and opportunities. While current technical indicators show mixed signals, the broader market forecasts suggest potential upside. Traders should remain vigilant, keeping an eye on macroeconomic developments and market trends for further clues about where BTCUSD is headed.
As of now, BTCUSD is priced at $87,877.29 with a 0.81% increase over the last day. Visit our detailed analysis page for more insights here.
Monthly targets are set at $91,771.03, while quarterly forecasts suggest a rise to $137,052.42. Long-term projections estimate a price of $133,253.33 over five years.
Technical indicators present mixed signals. The RSI suggests possible room for a rebound, while the MACD shows bearish momentum, indicating caution is warranted.
Bitcoin’s performance is impacted by various market sentiments and simple updates, with no major events altering its recent trajectory significantly. Volatility remains a key factor.
With mixed technical signals and a cautious yet optimistic market forecast, Bitcoin reaching $92,000 depends on multiple factors including macroeconomic conditions.
Disclaimer:
Cryptocurrency markets are highly volatile. This content is for informational purposes only.
The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice.
Meyka AI PTY LTD provides market data and sentiment analysis, not financial advice.
Always do your own research and consider consulting a licensed financial advisor before making investment decisions.
Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.
The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.
The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.
There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.
GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.
• Our writers’ share tips for 2026, plus last year’s winners and losers
Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.
M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.
Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.
“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important. These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”
Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.
The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.
While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.
Solana price trades below $130 as whale short positions and bearish chart structures keep downside levels around $105 and $78 firmly in focus.
Solana price is trading around the $125–$127 area, but short-term pressure remains heavy as sellers continue to defend overhead resistance and large players position for further downside.
While longer-term optimism around Solana remains intact, recent price action and trader commentary suggest that SOL may not be done correcting yet, with several market watchers pointing to lower support zones before any meaningful recovery attempt.
Solana current price is $127.15, up 2.16% in the last 24 hours. Source: Brave New Coin
Solana price is currently trading near $127, according to data from Brave New Coin. Despite a minor bounce, price remains well below key weekly levels, keeping short-term momentum tilted to the downside.
One of the clearest short-term bearish signals comes from positioning data shared by analyst Ted Pillows. His chart highlights a large trader actively holding short exposure across major assets, including a $43.1 million short position in SOL, alongside significant shorts in Bitcoin and Ethereum.

A major whale continues to hold a $43.1M short position in SOL. Source: Ted Pillows via X
Such positioning suggests that large players are still leaning towards further downside or, at a minimum, continued weakness below resistance. While whale positions do not guarantee immediate follow-through, they often align with prevailing market sentiment. In this case, SOL remains below key resistance zones, making it difficult for upside moves to gain traction.
Until price invalidates this positioning by reclaiming higher levels, the presence of sizeable short exposure keeps the short-term outlook tilted toward caution rather than confidence.
Adding to the downside case, analyst Elite Crypto pointed to a bearish head-and-shoulders pattern forming on Solana’s higher-timeframe chart. According to his analysis, the structure remains intact as long as SOL trades below key resistance, with $105 acting as the critical neckline support.

A bearish head-and-shoulders structure keeps $105 in focus, with a clean breakdown potentially opening the door to a much deeper corrective move. Source: Elite Crypto via X
A decisive break below this level would significantly weaken the broader structure and open the door to a deeper corrective move. Elite Crypto highlighted potential downside targets in the $75–$51 range, suggesting that, if triggered, the correction could extend well beyond a short-term pullback and persist into mid-2026.
While this scenario is conditional, it reinforces why many traders remain defensive at current prices despite recent rebounds.
Another bearish-to-neutral perspective comes from analyst StefanB, who shared that he is only interested in accumulating Solana at much lower levels. His analysis highlights the $78 region, aligning with the 0.786 Fibonacci retracement, as a zone where long-term risk-reward becomes more attractive.

The $78 level stands out as a potential long-term accumulation zone, aligning with the 0.786 Fibonacci retracement where deeper demand could emerge. Source: StefanB via X
This approach implies that current prices may still sit above areas where stronger demand is expected to emerge. Rather than chasing short-term bounces, StefanB’s positioning suggests patience, with bids placed at levels that coincide with historical structure and deeper retracements.
Taken together with the $105 breakdown risk, this frames the current price zone as transitional rather than a confirmed bottom.
While short-term and medium-term signals lean bearish, longer-term charts introduce a conditional bullish element. Analyst ShardiB noted that Solana is currently interacting with its 200-week moving average, a level that has historically acted as major long-term support.

Solana price tests its 200-week moving average, a level that has historically acted as long-term support and could mark an early base if price manages to hold. Source: ShardiB via X
According to the analysis, Solana price is attempting to form a base near this zone, with early signs of a potential weekly bottom candle developing. In previous cycles, sustained holds above the 200-week level have often preceded longer-term recovery phases, though not without extended consolidation.
However, ShardiB also cautioned that failure to hold this area would significantly weaken the long-term outlook, reinforcing that bullish scenarios remain conditional rather than guaranteed.
In the short term, Solana remains vulnerable below key resistance, with downside levels clearly defined. As long as Solana price trades below the $135–$140 region, attention remains on $120 and, more importantly, $105 as critical support levels.
A confirmed break below $105 would increase the probability of a deeper move towards $78, with further downside towards the $75–$51 zone possible if broader market conditions deteriorate. These levels align with multiple market watchers projections and higher-timeframe structures.
On the upside, any meaningful bullish shift would likely require SOL Solana price to hold long-term support and reclaim higher resistance levels over time. Such a move would signal that the corrective phase is transitioning into a broader base-building process rather than immediate trend reversal.
Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.